• Omeprazole (A2845): Protocol and QC Guide

  2026-08-11

  Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, acid-formation assays, and antiulcer activity studies. This guide covers preparation, assay controls, storage, and failure prevention; the material is for scientific research only and not for diagnostic, clinical, or therapeutic use.

• Aprotinin: Protease Control in Nascent RNA Assays

  2026-08-11

  Aprotinin, or bovine pancreatic trypsin inhibitor, is best understood not only as a fibrinolysis-modulating reagent but also as a variable in preanalytical assay design. This article connects its serine-protease pharmacology with the rRNA-depleted GRO-seq workflow and defines where that cross-domain application is useful, unvalidated, or potentially misleading.

• IL-17A and Neonatal Risk in GBS-Colonized Pregnancies

  2026-08-10

  A prospective mother–newborn study in Morocco found that reduced maternal IL-17A, alongside lower IL-1β and IL-4 responses, was associated with invasive GBS disease in newborns. The work positions circulating IL-17A as a candidate risk-stratification biomarker and shows how ex vivo TLR1/2 and TLR4 stimulation can complement clinical cytokine profiling.

• MTT Assays for Drug-Resistant Cancer Translation

  2026-08-09

  A mechanism-first guide to using MTT as a metabolic readout in drug-resistant cancer research, with translational strategy for nanoparticle evaluation, assay design, interpretation, and product selection.

• How Cholesterol Hinders LNP Intracellular Trafficking

  2026-08-08

  The reference study introduces a sensitive streptavidin–biotin-DNA tracking and high-throughput imaging strategy to resolve how lipid nanoparticle composition affects intracellular movement. Its central finding is that excess cholesterol promotes aggregation of LNP-containing peripheral early endosomes, limiting endolysosomal progression and reducing nucleic-acid delivery efficiency.

• Reversine Aurora Kinase Inhibitor Workflows

  2026-08-07

  Reversine connects mechanistic mitosis research with practical cancer-cell assays and emerging single-object gastruloid screening. This guide explains dose design, apoptosis and cell-cycle readouts, microraft-compatible workflows, and troubleshooting for reproducible Aurora kinase studies.

• Synergistic CDK4/6 and BET Inhibition Suppresses PDAC via Wn

  2026-08-07

  Gu et al. (2025) demonstrate that combined CDK4/6 and BET inhibition yields synergistic suppression of pancreatic ductal adenocarcinoma growth and epithelial-to-mesenchymal transition by modulating the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight informs targeted combination strategies for overcoming tumor progression and metastatic risk in pancreatic cancer.

• Adipose-Neural Axis and Cardiac Arrhythmias: Leptin–NPY/Y1R

  2026-08-06

  Fan et al. (2024) present a stem cell-based coculture model revealing the critical role of the adipose-neural axis, specifically the leptin–NPY/Y1 receptor pathway, in epicardial adipose tissue (EAT)-related cardiac arrhythmias. Their findings highlight new mechanistic insights and therapeutic targets for atrial fibrillation and related conditions.

• Syringin Natural Product: Mechanistic Leverage in RCC Resear

  2026-08-06

  This thought-leadership article explores the emerging role of Syringin, a bioactive natural product, in overcoming sunitinib resistance in renal cell carcinoma (RCC) via EGFR/PI3K/Akt pathway modulation. Integrating mechanistic insights, experimental guidance, and strategic outlook, it empowers translational researchers to navigate and accelerate bioactive compound innovation.

• NADPH Oxidase-ROS Drive Arterial Contraction via L-type Ca2+

  2026-08-05

  A recent study clarifies how NADPH oxidase-derived reactive oxygen species (ROS) promote arterial contraction in early postnatal rats, revealing a direct role for L-type voltage-gated Ca2+ channels (LTCC) rather than classical kinase pathways. These insights refine our understanding of vascular developmental biology and the specificity of ROS signaling.

• PCI-32765 (Ibrutinib): Applied BTK Inhibition for B-Cell Stu

  2026-08-05

  PCI-32765 (Ibrutinib) offers robust, irreversible BTK inhibition, empowering researchers to precisely dissect B-cell receptor signaling and model disease-relevant phenotypes. This guide delivers actionable workflow enhancements, troubleshooting strategies, and evidence-backed assay parameters for chronic lymphocytic leukemia and autoimmune disease research.

• DiscoveryProbe FDA-approved Drug Library in HTS: Protocols &

  2026-08-04

  The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) empowers high-throughput drug repositioning and pharmacological target identification with 2,320 clinically approved compounds in ready-to-screen formats. This article details advanced experimental workflows, troubleshooting strategies, and real-world application examples, enabling researchers to accelerate discovery in oncology, neuroscience, and GPCR biology.

• METTL17 Regulates Ferroptosis via Mitochondrial Translation

  2026-08-04

  This study uncovers how the mitochondrial protein METTL17 confers ferroptosis resistance and promotes tumorigenesis in colorectal cancer by regulating mitochondrial RNA methylation and translation. The identification of METTL17 as a modulator of mitochondrial function and cell death highlights a promising therapeutic target for sensitizing colorectal tumors to ferroptosis-based interventions.

• GRA12: A Conserved Virulence Factor Across Toxoplasma Strain

  2026-08-03

  A recent in vivo CRISPR screen identifies GRA12 as a key, conserved secreted virulence factor required for acute Toxoplasma gondii infection across diverse parasite strains and mouse subspecies. These findings reframe our understanding of host-pathogen interactions and open new avenues for targeting immune evasion in apicomplexan parasites.

• Synergistic CDK4/6 and BET Inhibition in Pancreatic Cancer

  2026-08-03

  Gu et al. demonstrate that combining CDK4/6 and BET inhibitors yields a synergistic effect against pancreatic ductal adenocarcinoma (PDAC), suppressing both tumor growth and epithelial-to-mesenchymal transition (EMT) via modulation of the GSK3β-mediated Wnt/β-catenin pathway. These findings suggest a promising combinatorial strategy to overcome the limitations of monotherapy and address metastatic progression in PDAC.

16373 records 1/1092 page Next 12345 下5页 Last page